Glox Therapeutics

Glox Therapeutics develops precision antibiotic therapies to combat antimicrobial resistance.

Glasgow, UK—Founded 2023—Website

£4.3MTotal raised

Glox Therapeutics develops precision antibiotic therapies using naturally occurring bacteriocins to target antimicrobial-resistant pathogens. The company emerged as a spin-out from the Universities of Glasgow and Oxford.

Founders

Daniel Walker

Professor

Daniel serves as chief scientific officer at Glox Therapeutics and professor of microbiology at the University of Strathclyde. He previously held professorial and research roles at the University of Glasgow.

Colin Kleanthous

Professor